Navigation Links
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
Date:10/27/2011

SILVER SPRING, Md., Oct. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2011.

"We achieved over $200 million in revenues this quarter, which reflects the continued strength of our core business," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "I'm also pleased that our Board of Directors recently authorized a $300 million share repurchase program, which has already begun to return additional value to our shareholders."

Total revenues for the quarter ended September 30, 2011 were $201.7 million, up from $168.6 million for the quarter ended September 30, 2010. Net income for the quarter ended September 30, 2011 was $84.4 million or $1.45 per basic share, compared to $39.7 million or $0.70 per basic share for the same quarter in 2010. Gross margin from sales was $178.3 million for the quarter ended September 30, 2011, compared to $148.1 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended September 30, 2011 were $100.8 million, compared to $99.3 million for the quarter ended September 30, 2010.

Financial Results for the Three Months Ended September 30, 2011Revenues

The table below summarizes the components of net revenues (dollars in thousands):Three Months EndedSeptember 30,20112010PercentageChangeCardiopulmonary products:Remodulin

$

114,918$

109,5844.9%Tyvaso

66,33048,71736.2%Adcirca

19,7729,93599.0%Other

722339113.0%Total net revenues

$

201,742$

168,57519.7%Revenues for the quarter ended September 30, 2011 increased by $33.2 million, compared to the quarter ended September 30, 2010. The growth in revenues primarily reflects the increase in the number of patients being prescribed our produc
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report
2. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
3. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
4. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
5. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
6. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
7. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
8. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
9. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
10. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
11. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
(Date:7/31/2014)... SAN DIEGO and SHENZHEN, China ... Genomics announced today the purchase of an ... genomics organization. BGI selected BioNano,s platform to enable comprehensive ... vastly improved assemblies for various organisms of interest, including ... BGI will partner together to develop new methods for ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Rancho ... the integration of Omicsoft’s Array Suite with tranSMART ... will be able to send data in tranSMART to ... with all versions of tranSMART including the new 1.2 ... statistics, visualization and storage for the analysis of high ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... M2S Expert Dr. Steven Marra will give the ... Sigma in the Imaging Core Lab" at the ... for Clinical Trials conference. Dr. Marra,s presentation will ... principles have contributed to the development of the ...
... -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: PXSL ... Fox,to its senior management team in the position of ... regulatory affairs, pharmacovigilance and,medical affairs. Clinical Operations will ... , Dr Fox has more ...
... journal, Science, reports that advanced cholesterol test aids in ... BIRMINGHAM, Ala., Feb. 16 ... University of Maryland researchers have found an association ... information reported in a recent study could help in ...
Cached Biology Technology:M2S Expert gives address "Applying the Principles of Six Sigma in the Imaging Core Lab" at Imaging for Clinical Trials conference 2Pharmaxis Builds Senior Management Team 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 3VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 4
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... effect in 1839, humankind has sought to further understand ... purposes. In a new research report published in the ... , scientists may have uncovered a new method ... a naturally occurring combination of lipids that have been ... and across speciessuggests that this specific natural combination of ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2
... believes that changes in behaviour among the population have accelerated ... Research published today in Science shows how there has been ... groups, which the researchers attribute to people delaying when they ... found HIV prevalence fell most steeply at young ages, with ...
... venom could provide the next generation of human therapeutic ... been identified by Queensland University of Technology PhD researcher ... vascular surgery and major trauma. , The genetic code ... by PhD researcher Liam St Pierre from QUT's School ...
... a case of evolutionary detective work. Biology researchers at ... have found evidence for an ancient transfer of a ... a bacterium. But the mystery remains as how the ... published this month in the journal Bioinformatics, 22(3): 264-268, ...
Cached Biology News:HIV decline in Zimbabwe linked to behavioural change 2Taipan venom no snake oil 2Evolution mystery: Spider venom and bacteria share same toxin 2
... highly versatile power supply. Capable of producing up ... supply is ideal for PAGE, SDS-PAGE, DNA or ... of small format transfer apparatus. It is designed ... with a continuously variable output in either mode. ...
... supply is a highly compact, extremely reliable and ... knob and one hi-lo range switch control the ... from 20 to 250 volts. One two-position switch ... voltage to output current. For maximum safety, the ...
... a recombinant 177 amino acid polypeptide sequence ... human MT1-MMP. Produced by activation of ... from E. coli periplasm. SPECIFIC ACTIVITY:The ... = 140 mU/mg, where 1 U is ...
... mM sodium phosphate buffer, pH 6.5. Cathepsin ... a major lysosomal aspartyl protease in mammalian ... Overexpression of cathepsin D in human breast ... relapse and metastasis. Cathepsin D degrades extracellular ...
Biology Products: